Time-Dependent vs Concentration-Dependent Antimicrobial Activity

Learning Objective 4 – Contrast Time-Dependent and Concentration-Dependent Antimicrobial Activity

Core Distinction

• Time-Dependent Killing

  • Therapeutic success relies on how long plasma/ tissue levels remain above the organism’s minimum inhibitory (or effective) concentration (MIC / MEC), not on how high the peak is.

  • Key pharmacodynamic metric: \text{\%Time} > \text{MIC}

  • Once drug levels sit modestly above $MIC$, raising the dose generally does not increase bacterial kill – only prolonging exposure does.

• Concentration-Dependent Killing

  • Efficacy driven by the magnitude of the peak concentration (often expressed as $C_{\text{max}}$) relative to $MIC$.

  • Key metric: $\frac{C_{\text{max}}}{MIC}$ (or the related $AUC/MIC$ for some agents).

  • A single, high peak produces rapid microbial death; sustained exposure is less critical once the intracellular effect has occurred.

Time-Dependent Agents

• Prototype: Penicillins (other β-lactams, macrolides, clindamycin, etc.)

• Mechanistic note

  • β-lactams inhibit cell-wall transpeptidases → cell-wall synthesis blockade → bactericidal action during active cell-wall construction.

  • Requires continuous presence (≈ 60 % of each dosing interval) above MEC to disrupt the wall as the bacterium grows.

• Dosing/administration implications

  • Frequent smaller doses (e.g., q6h) or continuous/prolonged infusions to keep levels above $MIC$.

  • Increasing a single dose without lengthening contact time provides little added benefit.

• Clinical relevance

  • Ward observation: patients on IV benzyl-penicillin may receive up to 6 doses/day.

  • Nursing role: ensure dose timing; missed/late doses can drop \text{\%Time} > \text{MIC} below the 60 % target, risking therapeutic failure.

Concentration-Dependent Agents

• Prototype: Aminoglycosides (e.g., gentamicin)

  • Other examples: fluoroquinolones, daptomycin, metronidazole.

• Mechanistic note

  • Aminoglycosides bind the 30 S ribosomal subunit → misreading of mRNA → rapid bacterial death once a high intracellular burst is achieved.

  • They also exhibit a post-antibiotic effect (PAE): continued suppression of growth even after plasma levels fall below $MIC$.

• Dosing/administration implications

  • Once-daily high-dose regimens common (e.g., gentamicin 5–7 mg/kg IV every 24 h) to maximize $C_{\text{max}}$ while exploiting PAE.

  • Monitoring focuses on peak (for efficacy) and trough (for toxicity risk).

• Clinical relevance

  • Pharmacy & nursing must coordinate timed blood samples (30 min post-infusion peak, just-before-next-dose trough) to adjust dosage.

  • Avoids nephro- and oto-toxicity by allowing sub-MIC levels for part of the interval.

Practical & Ethical Considerations

• Patient safety: Incorrect understanding of the PK/PD driver can lead to under-dosing (treatment failure) or overdosing (toxicity).

• Stewardship: Appropriate dosing regimens minimize resistance; e.g., β-lactam under-exposure selects for resistant sub-populations.

• Hospital workflow: Time-dependent agents create scheduling complexity; concentration-dependent agents demand serum-level monitoring.

Key Take-Home Formulas & Ratios

• Time-dependent target:
  \text{\%Time} > MIC \ge 60\% (β-lactams)

• Concentration-dependent targets:
  $\frac{C<em>{\text{max}}}{MIC} \ge 10$ (aminoglycosides) $\frac{AUC</em>{0-24}}{MIC}$ thresholds vary by class (e.g., $\ge 125$ for fluoroquinolones against Gram-negatives).

Quick Comparison Table (Mental Checklist)

• Driver: Time vs Peak

• Dose Strategy: Frequent/continuous vs High-dose, infrequent

• Examples: Penicillins vs Gentamicin

• Main Metric: \text{\%Time} > MIC vs $C_{\text{max}}/MIC$

• Post-Antibiotic Effect: Minimal vs Pronounced

• Clinical Focus: Schedule adherence vs Level monitoring

Connections to Previous/Foundation Concepts

• Builds on earlier pharmacokinetics (absorption, distribution, metabolism, elimination) by mapping them to pharmacodynamics (kill characteristics).

• Reinforces significance of half-life ($t<em>{1/2}$): longer $t</em>{1/2}$ simplifies maintaining \text{\%Time} > MIC.

• Links to lecture on bacterial growth phases: β-lactams need actively dividing cells → why constant exposure matters.

Hypothetical Scenario (Integrative Application)

"Patient A" with severe pneumonia receives piperacillin-tazobactam 4 g q8h by extended infusion over 4 h.
• Rationale: extend \text{\%Time} > MIC for a pathogen with high MIC.
"Patient B" with the same pathogen but normal renal function gets gentamicin 6 mg/kg IV once daily.
• Goal: achieve $C_{\text{max}}$ ≈ 10×MIC, exploit PAE, and provide kidney recovery time.

Comparing the two highlights how the same bug can be tackled with two opposite PK/PD philosophies depending on drug class.